Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

Main Inclusion Criteria:

• Histologically confirmed, unresectable, locally advanced or metastatic solid tumorsthat are known to express Nectin-4

• Prior systemic treatment for locally advanced or metastatic disease, yet no therapywith demonstrated clinical benefit for the tumor type is available.

• Measurable disease according to RECIST 1.1.

• Archival tumor tissue obtained within 4 months of screening and since the lastanticancer therapy prior to the study or agree to undergo a tumor biopsy atbaseline.

• Adequate organ function and hematological function.

Main Exclusion Criteria:

• Known or suspected brain metastases.

• Participants with an active infection, Any other infection requiring systemictreatment or latent infection.

• Participants with clinically significant comorbidity(s).

• History of treatment for, or suspicion or confirmed interstitial lung disease (ILD)at baseline.

• Condition being treated with systemic corticosteroids or immunosuppressive therapyduring IPH4502 treatment.

• Thromboembolic event requiring anticoagulation therapy ≤14 days prior to the firstdose of IPH4502.

• Clinically significant cardiovascular disease and/or cardiac repolarizationabnormality.

• Participants with symptomatic heart failure, Acute coronary syndromes

• Participant is receiving or has received anticancer therapy prior to enrolment thatmay have impact on the assessment of IPH4502.

• Major surgery ≤28 days and minor surgery ≤7 days prior to first dose of IPH4502 or 6months for coronary artery bypass surgery.

• Concomitant medications or vaccines : Live-attenuated vaccines ≤ 6 weeks prior tofirst dose of IPH4502; systemic corticosteroids or other immunosuppressive agentswithin 14 days prior to the first dose of IPH4502; systemic use of moderate orstrong CYP 3A4 inhibitors; systemic use of moderate or strong CYP 3A4 inducers.